Pfizer Inc. has identified new indole analogues acting as sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of diabetes, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease (NAFLD; MASLD), phenylketonuria, metabolic syndrome, obesity, neurodevelopmental and autism-spectrum disorders, among others.
Confo Therapeutics NV has secured a 2-year €1 million (US$1.2 million) grant from Flanders Innovation & Entrepreneurship (VLAIO) to advance research and development of ultra-long-acting medicines targeting G protein-coupled receptors (GPCRs), including bi- and multispecific antibody formats for obesity and other metabolic and endocrine disorders.
Nilo Therapeutics Inc. has launched with a $101 million series A financing and a focus on harnessing neural circuits to restore immune homeostasis in disease.
Researchers at Hefei Amvite Pharmaceutical Co. Ltd. reported the discovery and preclinical evaluation of a series of structurally modified ziritaxestat derivatives, leading to the identification of more potent autotaxin inhibitors.
A new study aimed to investigate the therapeutic effect of ISM012-042 in a chronic T-cell transfer-induced colitis model in mice that mimicked Crohn’s disease.
Tessera Therapeutics Inc. has been awarded up to $41.3 million from the Advanced Research Projects Agency for Health (ARPA-H) as part of its EMBODY (Engineering of immune cells inside the body) program to support the development of Tessera’s in vivo CAR T therapy efforts.
Boehringer Ingelheim Pharma GmbH & Co KG has signed an asset purchase agreement with Accent Therapeutics Inc. for Accent’s preclinical small-molecule program that offers a novel approach for treating tumors with high interferon-stimulated gene (ISG) expression.
Glycovax Pharma Inc. has entered into a strategic collaboration with the National Research Council of Canada (NRC) and the Université de Montréal to develop a glycoconjugate vaccine against Pseudomonas aeruginosa infections, with expected utility for patients with cystic fibrosis and hospitalized individuals at risk of nosocomial infections.
Oligomeric forms of α-synuclein are increasingly recognized as the primary neurotoxic species in Parkinson’s disease (PD) and other synucleinopathies, contributing to synaptic dysfunction, mitochondrial impairment and the prion-like propagation of pathology. Targeting these early aggregates represents a promising strategy for disease modification.
RSS
